Advertisement
Advertisement
U.S. markets close in 3 hours 23 minutes
Advertisement
Advertisement
Advertisement
Advertisement

First Wave BioPharma, Inc. (FWBI)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.2187-0.0061 (-2.71%)
As of 12:32PM EDT. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Relative Strength Index (RSI)

Relative Strength Index (RSI)

Previous Close0.2248
Open0.2200
Bid0.2078 x 800
Ask0.2080 x 1200
Day's Range0.2016 - 0.2200
52 Week Range0.1900 - 8.5700
Volume972,860
Avg. Volume664,886
Market Cap4.732M
Beta (5Y Monthly)1.81
PE Ratio (TTM)N/A
EPS (TTM)-5.6750
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est14.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for FWBI

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • First Wave BioPharma, Inc.
    The Argus Dividend Growth Model PortfolioDividend income, an important element of total return, is often overlooked amid gyrations in the stock market. Between 1930 and 2012, dividend income accounted for 42% of the total return of the S&P 500, according to Hartford Funds. And that's just the average. In some decades, dividends accounted for more than 50% of total returns and even 100% of returns. More recently, dividends have accounted for 15%-20% of returns. Still, in 2018, dividend payments softened the blow when most market indices declined as the Federal Reserve hiked rates. The pattern is being repeated in 2022 as well. Not all dividends are created equal, though, and it is important to understand the difference between the two main categories: high-yield stocks and dividend-growth stocks.
    Rating
    Fair Value
    Economic Moat
    7 days agoArgus Research
View more
  • GlobeNewswire

    First Wave BioPharma to Participate in “Fireside Chat” at the H.C. Wainwright Global Investment Conference

    Fireside Chat scheduled for Tuesday, May 24, 2022, at 3:00 p.m., EDTBOCA RATON, Fla., May 17, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced today, that James Sapirstein, Chairman and Chief Executive Officer, will participate in a “fireside chat” with Yi Chen, Ph.D., Managing Di

  • GlobeNewswire

    First Wave BioPharma Chairman and CEO Issues Letter to Shareholders

    BOCA RATON, Fla., April 29, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that James Sapirstein, Chairman, President and CEO First Wave BioPharma, has issued a Letter to Shareholders to provide an update on recent events and an outlook for the Company’s clinical programs

  • GlobeNewswire

    First Wave BioPharma Forms Clinical Steering Committee Focused on Advancing Inflammatory Bowel Disease (IBD) Product Portfolio

    Committee members include globally renowned experts in gastrointestinal diseases, including ulcerative colitis and Crohn’s diseaseBOCA RATON, Fla., April 27, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced the formation of a clinical steering committee focused on advancing

Advertisement
Advertisement